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Abstract
Meningococcal meningitis remains a significant public health threat, especially in the African 
meningitis belt where Neisseria meningitidis serogroup A historically caused large-scale 
epidemics. With the rollout of a novel meningococcal serogroup A conjugate vaccine (MACV) in 
the belt, the World Health Organization recommended case-based meningitis surveillance to 
monitor MACV impact and meningitis epidemiology. In 2014, the MenAfriNet consortium was 
established to support strategic implementation of case-based meningitis surveillance in 5 key 
countries: Burkina Faso, Chad, Mali, Niger, and Togo. MenAfriNet aimed to develop a high-
quality surveillance network using standardized laboratory and data collection protocols, develop 
sustainable systems for data management and analysis to monitor MACV impact, and leverage the 
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surveillance platform to perform special studies. We describe the MenAfriNet consortium, its 
history, strategy, implementation, accomplishments, and challenges.
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Meningococcal meningitis, caused by the bacterium Neisseria meningitidis, remains a 
significant public health threat globally. The meningitis belt of sub-Saharan Africa—
stretching from Senegal to Ethiopia—experiences the highest disease burden, with more 
than 400 million people at risk in 26 countries [1]. Countries in the African meningitis belt 
have historically experienced annual seasonal outbreaks with explosive epidemics every 5 to 
10 years, with N meningitidis serogroup A (NmA) accounting for approximately 90% of 
cases during epidemics [1, 2]. After a large NmA epidemic in 1996-1997, which affected 
more 250 000 people and killed more than 25 000 people, African public health leaders 
signed the Yaounde Declaration, calling for the elimination of NmA epidemics in Africa [3]. 
In response, a low-cost meningococcal serogroup A conjugate vaccine ([MACV] 
MenAfriVac®) was developed solely for Africa [4]. The phased and rapid rollout of MACV 
starting in 2010 through mass vaccination campaigns drastically reduced NmA cases, 
eliminated NmA epidemics, and proved to be a highly effective intervention [2, 5, 6]. 
However, because MACV was licensed based solely on excellent safety and immunogenicity 
data without field effectiveness trials, there was a need to determine the direct and indirect 
effectiveness of this vaccine [7]. Several key questions remained including long-term 
effectiveness and impact of MACV on herd immunity and epidemiology of meningitis in 
Africa, potential meningococcal serogroup replacement, and the need for developing 
multivalent meningococcal conjugate vaccines for the region. To answer these questions, 
high-quality meningitis surveillance data in the meningitis belt were critical.
After MACV introduction, the World Health Organization (WHO) recommended 
implementing case-based meningitis surveillance in countries that introduced the vaccine 
[8]. Case-based surveillance includes systematic collection of epidemiologic, clinical, and 
laboratory data on each suspected case of meningitis year-round. Because bacterial 
meningitis can be caused by multiple pathogens with indistinguishable clinical 
presentations, including N meningitidis, Haemophilus influenzae, and Streptococcus 
pneumoniae, a key component of case-based meningitis surveillance is to collect 
cerebrospinal fluid (CSF) specimens and identify the causative pathogen via laboratory 
confirmation at a reference laboratory.
As a result of the WHO recommendation, the MenAfriNet consortium was established in 
2014 to support strategic implementation of case-based meningitis surveillance in 5 key 
countries in the African meningitis belt: Burkina Faso, Chad, Mali, Niger, and Togo (Figure 
1). MenAfriNet is an international consortium led and implemented by African Ministries of 
Health, Agence de Médicine Préventive (AMP), the US Centers for Disease Control and 
Prevention (CDC), and the WHO, with support and collaboration from other international 
and nongovernmental organizations. The primary goals of MenAfriNet were to (1) develop a 
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high-quality, sustainable, case-based meningitis surveillance network using standardized 
tools, (2) assess changes in meningitis epidemiology and vaccine impact, and (3) inform 
vaccine policy decisions and new vaccine development. In this study, we describe the 
MenAfriNet consortium, its history, strategy, implementation, accomplishments, and 
challenges.
HISTORY
MenAfriNet was built upon a long history of strong national meningitis surveillance in the 
African meningitis belt, supported by many international partners. Established by WHO in 
the 1990s, national meningitis surveillance systems in the region were built upon the 
Integrated Disease Surveillance and Response (IDSR) framework for aggregate case 
reporting. The goal of IDSR was to strengthen overall disease surveillance and response 
systems [9]. After the large meningitis epidemics of 1996-1997, WHO built upon the IDSR 
framework to develop Enhanced Meningitis Surveillance protocols, to detect and respond to 
meningitis epidemics early and appropriately [8]. These protocols were designed to improve 
data collection and reporting, along with laboratory confirmation in a subset of cases in each 
district that crossed a predefined threshold suggesting risk of a meningitis epidemic [10]. 
Enhanced Meningitis Surveillance also helped inform critical decisions regarding the use of 
meningococcal vaccine supply during an outbreak, particularly considering limited global 
vaccine stocks.
Multiple countries in the meningitis belt had existing IDSR and Enhanced Meningitis 
Surveillance systems; however, baseline evaluations found that although surveillance 
infrastructures were strong, opportunities existed for improving data management, specimen 
transport to reference laboratories, and laboratory capacity for confirming cases [11]. More 
importantly, neither of the existing surveillance systems provided representative case-level 
demographic data nor laboratory confirmation for a large proportion of cases, which are 
critical for evaluating the impact of new vaccines on disease burden. In 2010, WHO 
provided case-based surveillance guidelines for meningitis belt countries that built on IDSR 
and Enhanced Meningitis Surveillance with the goal of evaluating MACV impact and 
estimating the incidence of non-NmA meningococcal serogroups to better inform emergency 
stockpile and new vaccine development strategies [8]. MenAfriNet was created to assist 
countries in the technical implementation and improvement of case-based meningitis 
surveillance and use of these data to evaluate and inform meningitis vaccine programs.
STRATEGY
The MenAfriNet strategy included an approach that emphasized country-driven capacity 
building (bottom-up) rather than a partner-driven (top-down) effort. Although this approach 
was more challenging, MenAfriNet’s 5-year commitment established sustainable capacity in 
the partner countries in the form of a country-owned case-based meningitis surveillance 
system and research platform, where data were available for national authorities to inform 
key policy decisions. The MenAfriNet consortium drew on decades of experience in the 
region and identified 3 key domains of focus: epidemiology, laboratory confirmation, and 
data management (Figure 2).
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At the start of the project in 2014, the MenAfriNet consortium collaborated with partner 
countries to strengthen these domains through a cycle of support activities (Figure 2). The 
cycle started with an assessment of existing surveillance systems, followed by context-
appropriate technology transfer to fill gaps identified through the assessment, training of 
country partners, and providing consistent mentorship to ensure enhanced capacity was 
maintained. This cycle of support continued throughout the course of the project, which 
enabled countries to routinely assess and improve the quality of activities implemented. It 
allowed country officials to work with international partners, and later with colleagues in 
other participating countries, to fill technical gaps.
IMPLEMENTATION
Country Selection and Engagement
To help in selection of partner countries to be included in MenAfriNet, an initial gap 
analysis was conducted. In addition to country interest and commitment, the main drivers of 
the country selection process included the following: whether inclusion of the country would 
contribute to the epidemiologic understanding of MACV impact in the African meningitis 
belt, existing in-country surveillance capacity, and resources needed to incorporate the 
existing system into the MenAfriNet network to collect high-quality, case-based data.
In 2014, MenAfriNet initially included 4 countries: Burkina Faso, Mali, Niger, and Togo. In 
2016, Chad was added as a fifth country. By the end of 2014, all 5 countries had conducted 
MACV mass vaccination campaigns (Table 1). Although all districts in Burkina Faso were 
included in MenAfriNet, Chad, Mali, Niger, and Togo concentrated their surveillance-
strengthening efforts in selected districts in the meningitis belt where meningitis disease 
burden was the greatest. By end of 2017, 115 (33%) of 347 districts in Burkina Faso, Chad, 
Mali, Niger, and Togo were included in MenAfriNet and approximately 33 million people 
were under MenAfriNet surveillance (Table 1).
Based upon past experience with project implementation in the African meningitis belt, it 
was clear that MenAfriNet’s successful completion, impact, and sustainability depended on 
early engagement and strong support from in-country partners, WHO offices, and, most 
importantly, the Ministries of Health [12]. Hence, countries and partners were engaged early 
on through joint missions to meet with Ministry of Health officials to extend formal 
invitations to join the consortium with emphasis on local capacity building and country 
ownership of surveillance data and activities. Countries developed annual work plans, 
outlining detailed activities to implement case-based meningitis surveillance with a clear 
focus on improving epidemiology, laboratory, and data management systems (DMSs).
To implement MenAfriNet activities, 5 work groups were formed and charged with key 
functions: (1) surveillance and outbreak, (2) laboratory, (3) data management, (4) research 
and evaluation, and (5) communications. Representatives from partner organizations chaired 
the work groups and were supported and organized by a CDC co-lead. Each work group 
held monthly or quarterly teleconferences and had a specific mission that defined the scope 
of work, frequency of communication, and guided activity implementation (Appendix 1). 
The work groups were tasked with developing standardized operating procedures, tools, 
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training materials, and carrying out mission-related activities relevant to the goal of the work 
group. In general, during the development and implementation stages of MenAfriNet 
activities, these work groups communicated via teleconference more frequently (ie, 
monthly); as activities moved into the maintenance phase, work groups transitioned to 
meeting less frequently (ie, quarterly).
Strengthening Case-Based Surveillance
To establish a high-quality, case-based meningitis surveillance network, MenAfriNet used 
several mechanisms to strengthen epidemiologic, laboratory, and data management capacity. 
Epidemiologic capacity was strengthened by developing standardized protocols and case 
investigation forms, identifying minimal data elements to be reported by each country, and 
developing surveillance performance indicators with target thresholds [13]. These tools 
facilitated data entry and transfer from the district to national level on a timely basis in each 
country and provided a common framework for surveillance activities in the region. Training 
workshops were held in each country to adapt these tools and implement new surveillance 
protocols.
To improve laboratory capacity, reference laboratories were identified at the national or 
regional level in each country. Lumbar puncture kits and Trans-isolate (TI) media were 
provided for CSF collection and transportation from diagnosing health facilities to reference 
laboratories. Direct real-time polymerase chain reaction (rt-PCR) testing was implemented 
in each country as a confirmatory test, to help increase diagnostic capacity in settings where 
culture-based methods were challenging. MenAfriNet trained public health laboratory 
scientists on specimen handling, diagnostic methods (ie, direct rt-PCR and bacterial culture), 
and laboratory data management and reporting [14]. MenAfriNet also implemented external 
quality-control and quality-assurance programs at the reference laboratories and assisted 
countries in procuring laboratory supplies needed for meningitis diagnostics.
To improve data management capacity, national level data managers and epidemiologists 
were trained in integrating laboratory data with clinical and demographic data into 1 master 
database with a unique identification number for each case. The MenAfriNet consortium 
developed an EpiInfo 7-based DMS that standardized data collection, transmission, and data 
harmonization among all MenAfriNet countries. MenAfriNet provided direct technical 
assistance in rollout of the DMS and held multiple training workshops for country data 
managers. In subsequent years, targeted workshops focusing on specific topics were held in 
each country to address ongoing data management gaps. Case-based data collected by 
MenAfriNet countries were sent to members of the WHO-AFRO, CDC, and AMP data 
management team to be merged into a central MenAfriNet database. Data were cleaned and 
analyzed to guide public health responses, monitor performance of the system using 
surveillance indicators, and provide critical feedback to countries. Data were also published 
in quarterly bulletins and presented at the annual WHO meeting on epidemic meningitis and 
at the annual MenAfriNet partners’ meeting.
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ACCOMPLISHMENTS
MenAfriNet has been successful over its 5-year tenure in directly improving standardized 
meningitis case-based surveillance in 5 countries while also benefiting meningitis 
surveillance in the other African meningitis belt countries through standardized protocols, 
tools, and technical assistance [15, 16]. One of MenAfriNet’s biggest accomplishments has 
been the successful formation of a consortium of international partners and Ministries of 
Health committed to fighting meningitis in the region. This consortium has promoted 
country ownership, collaboration, communication, data sharing, and curation of best 
practices, and it supported the professional development of local public health leaders. 
Through MenAfriNet support, in-country laboratory capacity to test and confirm suspected 
meningitis cases improved. Before MenAfriNet, there was no direct rt-PCR capacity in the 5 
countries; all MenAfriNet countries now have the capacity to perform direct rt-PCR to test 
CSF specimens for N meningitidis, S pneumoniae, and H influenzae and to conduct 
serogroup testing for specimens that are positive for meningococcus [14].
MenAfriNet support has resulted in improvement in the quality and availability of 
meningitis surveillance data to measure impact of MACV and guide public health efforts to 
reduce meningitis disease burden [13]. For example, this case-based surveillance platform 
has enabled estimating population-based incidence of confirmed meningitis and better 
quantification of meningitis disease burden in the region [17], filling an important 
information gap that previously was not possible. High-quality laboratory MenAfriNet data 
have also been used by countries with outbreak response measures including their 
application to the International Coordinating Group on Vaccine Provision for Meningitis for 
obtaining access to meningitis vaccines for outbreak response. The case-based surveillance 
data from Burkina Faso has been instrumental for monitoring the epidemiology of bacterial 
meningitis post-MACV, as well as to detect and confirm 5 NmA cases, including the first 
documented case of MACV failure [18]. These data accelerated Burkina Faso’s timeline for 
conducting a catch-up campaign for children born after the initial MACV campaign and 
introducing MACV into the Expanded Programme on Immunization (EPI) for young 
children in an effort to halt NmA transmission.
The MenAfriNet network has also facilitated partner organizations and Ministry of Health 
staff in supporting each other, both in providing routine technical assistance for surveillance 
and in responding to several epidemics in the region. In 2014, scientists from the Burkina 
Faso National Reference Laboratory for meningitis hosted and trained laboratory scientists 
from Mali on direct rt-PCR and supplied them with necessary reagents and materials to do 
their own in-country testing for meningitis. In 2015, MenAfriNet personnel, including 
epidemiologists and laboratory scientists from Burkina Faso, aided Niger in responding to 
the first large-scale epidemic of N meningitidis serogroup C (NmC) meningitis [19]. In 
addition, in 2016, a NmC meningitis outbreak was detected in Ouelessebougou, a 
MenAfriNet district in Mali. Strong relationships between MenAfriNet partners and Mali 
health officials allowed rapid confirmation of the outbreak as NmC and implementation of 
an early vaccination campaign [20]. Also in 2016, AMP’s mobile laboratory was deployed 
in Togo to help confirm and characterize an N meningitidis serogroup W meningitis 
outbreak [21]. MenAfriNet provided Togo with CSF collection kits, TI media, and other 
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laboratory reagents to aid in testing. In 2017, Burkina Faso staff conducted a data validation 
workshop and then led data validation workshops with their counterparts in Niger, and 
officials from Niger then led a data validation workshop in Mali. These collaborations were 
characteristic examples of the intercountry “south-south” collaboration that has been 
fostered through the MenAfriNet consortium.
The MenAfriNet surveillance platform has also been effectively leveraged to answer priority 
research questions. To assess the long-term impact of MACV on the prevalence, serogroup 
distribution, and molecular characteristics of asymptomatic nasopharyngeal carriage of N 
meningitidis, particularly NmA, meningococcal carriage evaluations were conducted in 
Burkina Faso in 2016-2017. MenAfriNet data have contributed to cost-effectiveness studies 
of possible vaccination strategies for multivalent meningococcal conjugate vaccines. 
Burkina Faso’s case-based surveillance system has also proven to be a valuable platform for 
monitoring pneumococcal meningitis epidemiology [22] and evaluating the introduction of 
pneumococcal conjugate vaccine [23], and the strong collaboration among MenAfriNet 
partners in Burkina Faso laid the foundation for a nationwide vaccination coverage survey 
after MACV introduction into the routine immunization program [24].
CHALLENGES
The progress made through MenAfriNet did not come without challenges. Maintaining and 
promoting consistent communication between partners, especially communication between 
MenAfriNet countries to share lessons learned and coordinate regional meningitis activities 
proved to be a challenge from the outset. To address this, MenAfriNet work groups held 
regular teleconferences and in-person meetings to discuss technical issues and facilitate 
discussions between countries. The annual MenAfriNet partners’ meeting was also used as 
an opportunity to foster communication and coordination between all partners and countries.
Given the limited internet connectivity in the region, consistent transmission of case-based 
surveillance data at all levels along with a standardized system that could efficiently receive 
and merge data from all MenAfriNet countries posed a significant challenge. To that end, 
MenAfriNet partners worked with individual countries to develop plans for transmitting and 
compiling data at regular intervals. A standardized database management system was also 
developed that allowed data from all MenAfriNet countries to be harmonized and stored into 
a single database for analysis. The roll out of the database had its own challenges including 
delays in developing the system and database versions that required in-person installation in 
each country. To tackle these challenges and ensure that high-quality data were collected, 
MenAfriNet staff held annual data validation workshops to harmonize all data collected 
through the MenAfriNet network. In addition, an end-of-project data validation workshop 
was held to finalize data collected throughout the course of the project.
Another challenge was establishing and maintaining a functioning CSF specimen transport 
and tracking system. The limited resources, frequent stock out of CSF collection and 
transport materials, poor infrastructure, and long distances led to temporary interruption of 
specimen collection and led to long delays in the specimen getting to a reference laboratory 
for confirmatory testing. To address this issue, MenAfriNet partners designed and 
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implemented STELAB, first piloted in Burkina Faso. STELAB is a real-time specimen and 
data tracking system that facilitates specimen transport and data transfer from the diagnosing 
health facility to the national level with the ability to track specimen and data in real-time at 
all levels [25].
An unexpected challenge was the 2014-2016 Ebola virus disease epidemic in West Africa 
[26]. This unprecedented crisis necessarily diverted public health personnel, funds, and 
attention away from other health problems and disrupted travel to West Africa just as 
MenAfriNet was launching. Although the Ebola epidemic temporarily deprioritized 
MenAfriNet activities, the consortium’s partnerships were strengthened, and it continued to 
achieve planned milestones. Another challenge encountered was the geopolitical situation in 
MenAfriNet countries, complicating country priorities and partner travel. In response, 
MenAfriNet leveraged the in-country capacity it had built, relied upon regional partners to 
implement and support MenAfriNet activities, and rescheduled activities as needed.
CONCLUSIONS
The MenAfriNet model is a successful and expandable platform for implementing and 
strengthening high-quality, case-based meningitis surveillance, evaluating vaccine impact, 
responding to meningitis epidemics, and monitoring the changing epidemiology of bacterial 
meningitis in the African meningitis belt. Although the MenAfriNet consortium was 
established to specifically address meningococcal meningitis and evaluate the impact of 
MACV, it is also a valuable platform for evaluating the effectiveness of MACV integration 
into EPI programs, pneumococcal conjugate vaccines, and the potential future deployment 
of a multivalent meningococcal conjugate vaccine. Moving forward, MenAfriNet will 
leverage the surveillance and research platform and the strong international and intercountry 
partnerships established during its tenure to continue providing high-quality meningitis data 
and technical assistance to inform immunization policies in the region. In addition, it will 
make the standardized surveillance tools publically available to further strengthen 
surveillance and contribute to understanding the evolution of meningitis in the African 
meningitis belt [27].
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Figure 1. 
Countries in the African meningitis belt (in light gray) and the 5 MenAfriNet countries (in 
orange).
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Figure 2. 
The MenAfriNet model for surveillance strengthening. ID, infectious diseases; QA, quality 
assurance; QC, quality control.
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